Table 1.
Demographic and clinical characteristics of the BNT162b2 and mRNA-1273 volunteers.
| Characteristics | BNT162b2 | mRNA-1273 | p-value |
|---|---|---|---|
| Number of Patients | 21 | 19 | |
| Age (years), median (SEM) | 41.05 (±2.80) | 38.11 (±2.13) | 0.416 |
| Gender | 0.711 | ||
| Male | 4 | 5 | |
| Female | 17 | 14 | |
| Ethnicity | – | ||
| Caucasian | 21 | 19 | |
| Comorbidities | |||
| Current smoker | 5 | 4 | 1 |
| Ex-smoker | 3 | 0 | 0.232 |
| Hypertension | 1 | 0 | 1 |
| Heart disease | 0 | 0 | – |
| Immune disease | 1 | 0 | 1 |
| Obesity | 0 | 1 | 0.475 |
| Diabetes | 0 | 1 | 0.475 |
| Pulmonary disease | 4 | 0 | 0.107 |
| Renal disease | 0 | 0 | – |
| Hepatic disease | 0 | 0 | – |
| Neurological disease | 1 | 0 | 1 |
| Treatment | |||
| Acetaminophen | 18 | 12 | 0.148 |
| Ibuprofen | 2 | 4 | 0.397 |
Volunteers were divided into BNT162b2 or mRNA-1273 groups according to the vaccine received. Two-sample t-test with equal variances was used for comparison of age, and chi-squared tests were used for the rest of the demographic variables of the volunteers. p-value < 0.05 indicated statistical difference between groups. SEM, standard error of the mean.